Knight Therapeutics (TSE:GUD) Sets New 52-Week High - Still a Buy?

Key Points

• Knight Therapeutics shares hit a new 52-week high of C$6.48, closing slightly lower at C$6.45 with a trading volume of 94,534 shares.
• Analysts from Canaccord Genuity set a new price target of C$6.50 for Knight Therapeutics, with a consensus rating of "Strong Buy" and an average price target of C$7.15.
• The company maintains a solid financial position with a current ratio of 3.36 and a debt-to-equity ratio of 7.52, although its P/E ratio stands at -21.23.

Knight Therapeutics Inc. (TSE:GUD - Get Free Report)'s stock price reached a new 52-week high on Thursday . The stock traded as high as C$6.48 and last traded at C$6.45, with a volume of 94534 shares. The stock had previously closed at C$6.29.

Analyst Ratings Changes

Separately, Canaccord Genuity Group set a C$6.50 price target on Knight Therapeutics and gave the stock a "buy" rating in a report on Friday, May 9th. Two research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Strong Buy" and an average target price of C$7.15.

Knight Therapeutics Price Performance

The firm has a market capitalization of C$656.46 million, a P/E ratio of -21.67, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. The business has a 50-day moving average of C$6.04 and a 200 day moving average of C$5.88. The company has a current ratio of 3.36, a quick ratio of 1.79 and a debt-to-equity ratio of 7.52.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.